Ensysce Biosciences, Inc. (ENSC)
0.4705
-0.04
(-7.93%)
USD |
NASDAQ |
Oct 23, 16:00
0.465
-0.01
(-1.17%)
After-Hours: 20:00
Ensysce Biosciences Enterprise Value : 6.826M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 6.826M |
| October 22, 2026 | 7.483M |
| October 21, 2026 | 7.629M |
| October 20, 2026 | 7.282M |
| October 19, 2026 | 7.352M |
| October 16, 2026 | 7.602M |
| October 15, 2026 | 8.893M |
| October 14, 2026 | 8.295M |
| October 13, 2026 | 8.481M |
| October 12, 2026 | 8.212M |
| October 09, 2026 | 7.743M |
| October 08, 2026 | 6.623M |
| October 07, 2026 | 6.159M |
| October 06, 2026 | 6.166M |
| October 05, 2026 | 5.990M |
| October 02, 2026 | 5.601M |
| October 01, 2026 | 5.679M |
| September 30, 2026 | 5.938M |
| September 29, 2026 | 5.958M |
| September 28, 2026 | 5.700M |
| September 25, 2026 | 5.882M |
| September 24, 2026 | 5.684M |
| September 23, 2026 | 5.917M |
| September 22, 2026 | 6.153M |
| September 21, 2026 | 6.024M |
| Date | Value |
|---|---|
| September 18, 2026 | 6.625M |
| September 17, 2026 | 6.534M |
| September 16, 2026 | 6.458M |
| September 15, 2026 | 6.519M |
| September 14, 2026 | 7.003M |
| September 11, 2026 | 7.092M |
| September 10, 2026 | 7.563M |
| September 09, 2026 | 6.889M |
| September 08, 2026 | 6.867M |
| September 04, 2026 | 6.586M |
| September 03, 2026 | 6.331M |
| September 02, 2026 | 6.376M |
| September 01, 2026 | 5.489M |
| August 31, 2026 | 5.564M |
| August 28, 2026 | 5.680M |
| August 27, 2026 | 5.666M |
| August 26, 2026 | 5.877M |
| August 25, 2026 | 5.731M |
| August 24, 2026 | 5.049M |
| August 21, 2026 | 5.249M |
| August 20, 2026 | 5.322M |
| August 19, 2026 | 5.487M |
| August 18, 2026 | 5.439M |
| August 17, 2026 | 5.302M |
| August 14, 2026 | 5.680M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.571M |
| Revenue (Quarterly) | 1.164M |
| Total Expenses (Quarterly) | 3.735M |
| EPS Diluted (Quarterly) | -0.1972 |
| Gross Profit Margin (Quarterly) | 99.44% |
| Profit Margin (Quarterly) | -220.8% |
| Earnings Yield | -586.5% |
| Normalized Earnings Yield | -586.52 |